hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Shore Capital Reaffirms Buy Rating on hVIVO Despite Share Price Weakness
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
Evgen Pharma (AIM:EVG) welcomes a new chairman and Chief Financial Officer (CFO).
Evgen Pharma PLC (AIM: EVG), renowned for its advancements in sulforaphane-based medicine, recently revamped its board structure.
Evgen Pharma (AIM:EVG) celebrates the potential new formulation of its leading candidate.
Evgen Pharma PLC (AIM: EVG) has revealed the conclusive data from its Phase 1b study, which evaluated the new enteric-coated tablet formulation of its primary drug, SFX-01.
Evgen Pharma (AIM:EVG) shifts focus towards more lucrative collaborations as their partnership with JuvLife concludes.
Evgen Pharma PLC (AIM: EVG), a clinical-stage pharmaceutical development firm, has disclosed the termination of its patent and knowledge licence agreement with JuvLife Ltd, a subsidiary of Juvenescence Ltd.
4d Pharma PLC (AIM:DDDD) Cancellation of admission to trading on AIM
Leeds, UK, 15 February 2023 – 4D pharma plc (the “Company”) (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class
4d Pharma PLC (AIM:DDDD) Updated Results from Renal Cell Carcinoma Cohort
4D pharma Announces Updated Results from the Renal Cell Carcinoma Cohort of the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab)
4d Pharma PLC (AIM:DDDD) Update on Administration and Suspension of Trading
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Evgen Pharma PLC (AIM:EVG) Study started of new SFX-01 tablet formulation
First healthy volunteers dosed on schedule
4d Pharma PLC (AIM:DDDD) Blautix Phase II Clinical Trial Results Published
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
4d Pharma PLC (AIM:DDDD) MRx0518 poster presentations at SITC 2022
4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)